BioLineRx Receives Notice of Allowance from USPTO for New Patent on BL-1020, Extending Patent Protection Until 2031

  BioLineRx Receives Notice of Allowance from USPTO for New Patent on BL-1020,
  Extending Patent Protection Until 2031

   - New patent provides at least nine years of additional protection over
                         patents previously granted -

Business Wire

JERUSALEM -- September 24, 2012

BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development
company, announced today that a Notice of Allowance has been received from the
United States Patent and Trademark Office (USPTO) claiming the crystalline
form of BL-1020, a first-in-class orally available treatment for
schizophrenia. The patent, when granted, will be valid at least until 2031,
without taking into account any possible extension periods, which is nine
years longer than the granted patent coverage previously reported by the
Company. Corresponding patent applications are pending in Europe, Japan,
India, China, Brazil, Mexico, Canada, Australia and Israel.

"We are extremely pleased with the allowance of the patent covering BL-1020's
crystalline form by the USPTO. There is now a significantly longer period of
exclusivity to our lead product, which reflects substantial additional
progress in its development towards commercialization. This approval, together
with recent additional patent approvals regarding BL-1020 and other drug
candidates, is a testament to our focused and highly professional patent
application strategy,"  said Dr. Kinneret Savitsky, CEO of BioLineRx. "We
believe that the market potential for BL-1020 has increased over the past
several months, as some larger pharmaceutical companies have reported failures
during late-stage clinical trials, or have reduced the operations surrounding
their schizophrenia therapies due to loss of patent protection."

Dr. Savitsky continued, "Today, almost 1% of the world’s population suffers
from schizophrenia, most of whom suffer concomitant cognitive impairment that
may severely affect daily functioning. Whereas current therapies for
schizophrenia do not address this need, BL-1020 has shown to significantly
improve cognitive function in schizophrenia patients, and we are currently
conducting the Phase II/III CLARITY trial with BL-1020’s cognition enhancement
as its primary objective. We eagerly look forward to the expected results in
the second half of 2013.”

BL-1020's composition and its use for the treatment of schizophrenia are
covered by a separate family of issued patents or pending patent applications
in the U.S., Europe, Japan, India, China, Korea, Mexico, Israel and Australia.
The issued patents and any additional patents to be issued in the future based
on pending patent applications of this family will expire, without taking into
account any possible extension periods, in September 2022.

About BL-1020

BL-1020 is a first-in-class GABA-enhanced antipsychotic that combines dopamine
antagonism with GABAergic activity. BL-1020 has demonstrated high efficacy and
safety with minimal EPS and no metabolic side effects. Most importantly,
BL-1020 may have the potential to improve cognition, which is a significant
unmet medical need in schizophrenia and other neurological and psychiatric
disorders. Three clinical studies have confirmed the safety and efficacy of
BL-1020, while pre-clinical studies have also shown that BL-1020’s GABA
enhancement may provide the basis for improved cognition.

About Schizophrenia

Schizophrenia is a serious mental disorder that affects about 1% of the
world’s population. It is a multi-factorial disease characterized by delusions
and hallucinations, emotional withdrawal and apathy, poor attention and
disorganization. The worldwide antipsychotic therapeutic market in 2011 was
estimated at approximately $20 billion.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) has commenced a Phase II trial, and BL-8040 for treating
acute myeloid leukemia (AML) has completed Phase I. In addition, BioLineRx has
nine products in various pre-clinical development stages for a variety of
indications, including central nervous system diseases, infectious diseases,
cardiovascular and autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase III)
and commercialization. For more information on BioLineRx, please visit
www.biolinerx.com.

Various statements in this release concerning BioLineRx’s future expectations,
including specifically those related to the development and commercialization
of BL-1020, constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements include
words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and
describe opinions about future events. These forward-looking statements
involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new products; and
the ability to implement technological improvements. These and other factors
are more fully discussed in the “Risk Factors” section of BioLineRx’s most
recent annual report on Form 20-F filed with the Securities and Exchange
Commission on March 22, 2012. In addition, any forward-looking statements
represent BioLineRx’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date. BioLineRx
does not assume any obligation to update any forward-looking statements unless
required by law.

Contact:

KCSA Strategic Communications
Garth Russell / Todd Fromer
1 212-896-1250 / 1 212-896-1215
grussell@kcsa.com / tfromer@kcsa.com
or
BioLineRx
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipih@netvision.net.il